Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: Results of an open-label study
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: Results of an open-label study
复制标题
DOI：
10.4088/jcp.v60n0408
复制
发表时间：
1999-04-01
影响因子：
5.3
通讯作者：
Carta, MG
中科院分区：
文献类型：
--
作者：
Cabras, PL;Hardoy, MJ;Carta, MG
背景：本研究旨在评价加巴喷丁辅助治疗双相或分裂情感障碍伴躁狂或躁狂症状的疗效、耐受性和安全性。方法：25例符合DSM-IV诊断标准的双相情感障碍或分裂情感障碍患者接受了为期16周的开放试验，采用临床总体印象量表(CGI)和简明精神病评定量表(BPRS)评定症状严重程度。结果：22例患者(88%)完成了加巴喷丁16周的治疗，19例(76%)通过CGI和BPRS评分的变化判断为阳性反应。平均剂量为1440 mg/d。唯一的副作用是过度镇静，随着持续治疗而减少。结论：加巴喷丁对双相情感障碍和分裂情感障碍患者的躁狂和轻躁症有较好的疗效。如果在对照研究中得到证实，这些发现表明加巴喷丁代表了一种耐受性良好、快速起效的抗躁药。
Background: This study was carried out to evaluate the efficacy, tolerability, and safety of gabapentin as an adjunctive treatment in patients with bipolar or schizoaffective disorder with manic or hypomanic symptoms.Method: Twenty-five patients fulfilling DSM-IV diagnostic criteria for bipolar I disorder or schizoaffective disorder underwent a 16-week, open-trial treatment with gabapentin, Symptom severity was measured using the Clinical Global Impressions scale (CGI) and the Brief Psychiatric Rating Scale (BPRS). Baseline scores and final scores were compared by using the Student t test and the Friedman range variance analysis.Results: Twenty-two patients (88%) completed the 16 weeks of treatment with gabapentin; 19 (76%) had a positive response as measured by changes in CGI and BPRS scores. The mean dose was 1440 mg/day. The only side effect observed was oversedation, which decreased with continuing treatment.Conclusion: Gabapentin was effective in the treatment of mania and hypomania in patients with bipolar and schizoaffective disorders. If confirmed in controlled studies, these findings suggest that gabapentin represents a well-tolerated, rapidly acting antimanic agent.